
    
      This is a phase 3, randomized, placebo-controlled, multicenter, international study for the
      treatment of CIT in adult subjects receiving chemotherapy for the treatment of lymphomas,
      defined by 2 platelet counts < 30 x 10^9/L at least 7 days apart. The study will consist of a
      screening period of up to 4 weeks, a 16-week treatment period, an end-of-treatment (EOT)
      visit, and long-term follow-up.
    
  